BIOSPAIN 2026

The ongoing challenges at Europe's borders and beyond, the lingering effects of COVID-19, and the shifting landscape of biological threats have fundamentally reshaped the way Europe must approach its biologic sector. Vaccines, therapeutics, and diagnostics are no longer just healthcare solutions, they are essential strategic assets. Europe's ability to produce these tools quickly, at scale, and on home soil has become a cornerstone of both defense and crisis resilience.

This session brings together key leaders from Europe’s defense, health security, and intelligence sectors to tackle a crucial question: What infrastructure, coordination, procurement strategies, and alliance frameworks does Europe need to ensure its biologics production meets the demands of future crises? By leveraging lessons from recent events and the strategic insights currently driving EU and national plans, panelists will evaluate Europe’s manufacturing readiness, the strategic role of stockpiles, the integration of intelligence in preparedness, and the necessary public-private collaboration to turn strategic goals into operational capabilities.